Clinical Trials, Pipeline Developments, Financial Results, and New Appointments - Research Report on Amarin, Immunomedics, Seattle Genetics, Repros Therapeutics, and LifePoint Editor Note: For more information about this release, please scroll to bottom PR Newswire NEW YORK, August 29, 2013 NEW YORK, August 29, 2013 /PRNewswire/ -- Today, Analysts' Corner announced new research reports highlighting Amarin Corporation plc (NASDAQ: AMRN), Immunomedics, Inc. (NASDAQ: IMMU), Seattle Genetics, Inc. (NASDAQ: SGEN), Repros Therapeutics Inc. (NASDAQ: RPRX), and LifePoint Hospitals, Inc. (NASDAQ: LPNT). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below. Amarin Corporation plc Research Report On August 26, 2013, Amarin Corporation plc (Amarin) announced that it has submitted a Supplemental New Drug Application (sNDA) to the US Food and Drug Administration (FDA) for the approval of Novasep Group, S.A.S. (Novasep), through its subsidiary Finorga S.A.S. (Finorga), as an additional Vascepa (icosapent ethyl) active pharmaceutical ingredient (API) supplier. According to the Company, this submission contributes to the planned expansion of the Vascepa manufacturing supply chain and is additional progress toward the Company's goal to protect the commercial potential of Vascepa to beyond 2030 through a combination of patent protection, regulatory exclusivity, trade secrets and by taking advantage of manufacturing barriers to entry. Amarin also informed that Novasep - a global leader in purification technologies and API manufacturing, is building the world's largest chromatography plant using its proprietary chromatography technologies, to produce API on behalf of the Slanmhor consortium and Amarin. The Company anticipates this Novasep facility in Mourenx, France, to be qualified and operational for manufacturing in 2014. The Full Research Report on Amarin Corporation plc - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/7cf9_AMRN] -- Immunomedics, Inc. Research Report On August 22, 2013, Immunomedics, Inc. (Immunomedics) reported its Q4 FY 2013 and full-year FY 2013 (period ended June 30, 2013). The Company's total revenues increased 41.4% YoY to $1.4 million during Q4 FY 2013, but decreased 84.8% YoY to $5 million for FY 2013. Net loss attributable to Immunomedics stockholders was $7.7 million or $0.09 per diluted share in Q4 FY 2013, compared to net loss of $7.5 million or $0.10 per diluted share in Q4 FY 2012. Net loss was $12.2 million or $0.16 per diluted share in full-year FY 2013, compared to net income of $0.8 million or $0.01 per diluted share in FY 2012. Gerard G. Gorman, Senior Vice President Finance and CFO, said, "In order to continue the clinical development of our antibody-drug conjugate programs in patients with solid tumors, which have advanced into Phase II trials, and to pay for certain expenses to initiate the planned clivatuzumab trial for the treatment of patients with pancreatic cancer, which we anticipate to advance into Phase III in fiscal 2014, we expect cash requirements in fiscal year 2014 to increase to $24 to $26 million." The Full Research Report on Immunomedics, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/c20d_IMMU] -- Seattle Genetics, Inc. Research Report On August 15, 2013, Seattle Genetics, Inc. (Seattle Genetics) announced that it has initiated Phase 2 clinical trial evaluating ADCETRIS (brentuximab vedotin) in combination with RCHOP (A+RCHOP), the current standard frontline therapy, for newly diagnosed patients with diffuse large B-cell lymphoma (DLBCL). According to the Company, the primary object of study is to assess the complete remission rate and safety profile of the combination, while secondary endpoints include objective response rate, progression-free survival and overall survival. Clay B. Siegall, Ph.D., President and CEO at Seattle Genetics, said, "This trial will provide us with data on the tolerability of the combination, as well as the antitumor activity achieved by adding ADCETRIS to the current standard frontline regimen. In addition, based on interim findings from our trial in the relapsed setting in which objective responses were observed among patients with low or undetectable levels of CD30 by conventional screening methods, we will enroll high-risk DLBCL patients to this frontline trial without prescreening for CD30 expression." The Full Research Report on Seattle Genetics, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/ff98_SGEN] -- Repros Therapeutics Inc. Research Report On August 20, 2013, Repros Therapeutics Inc. (Repros) reported interim 6 month results from the first 150 subjects enrolled into the ongoing one year placebo controlled study to assess the effect of Androxal treatment of secondary hypogonadal men and its effects on bone mineral density. The Company stated that at the 6 month time point, there is no proof that Androxal reduces bone mineral density as assessed by DEXA scans. Repros also said that there is a consistent trend in many bone regions where an improvement of bone mineral in comparison to placebo is observed. The Company expects that topline results from the first 150 subjects who completed 12 months of exposure to be available by Q2 2014 and also said that the New Drug Application (NDA) for Androxal remains on track for submission in mid-2014. The Full Research Report on Repros Therapeutics Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/2334_RPRX] -- LifePoint Hospitals, Inc. Research Report On August 21, 2013, LifePoint Hospitals, Inc. (LifePoint) announced the appointment of Leif Murphy as the CFO, with effect from September 14, 2013. According to the Company, Murphy holds nearly 20 years of healthcare finance and development experience and prior to joining LifePoint in 2011, Murphy served as President and CEO of DSI Renal, Inc., and was also Senior Vice President and Treasurer at Caremark, Inc. The Full Research Report on LifePoint Hospitals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/f06d_LPNT] ---- EDITOR NOTES: 1.This is not company news. We are an independent source and our views do not reflect the companies mentioned. 2.Information in this release is fact checked and produced on a best efforts basis and reviewed by a CFA. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. 3.This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. 4.If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com. 5.For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com. 6.Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be. NOT FINANCIAL ADVICE Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. SOURCE Analysts' Corner Contact: Joe Thomas, +1-310-496-8071 (North America)
Clinical Trials, Pipeline Developments, Financial Results, and New Appointments - Research Report on Amarin, Immunomedics,
Press spacebar to pause and continue. Press esc to stop.